NXTS Nexentis Technologies Inc.
$0.58▲ +3.15%
Materials
Other
After hours
$0.53▼ -8.52%
Oct 27, 4:10 PM ET
Volume 145.2K
Avg Volume (10D) 126.1K
Key Metrics & Fundamentals
Market Cap
$1.38M
P/E Ratio
0.1
Div Yield
0.00%
52W Range
0.51 - 25.83
% vs 50 MA
-58.58%
% vs 200 MA
-87.06%
RSI-14
22.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
2.03
Free Cash Flow
-$623,000
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.61M
COGS
–
Operating Exp
$1.74M
Operating Income
-$1.74M
EBIT
-$1.74M
Pretax Income
-$11.18M
Net Income
-$11.15M
EPS (Diluted)
-13.66
Price & Volume History
Loading chart…
Recent News
Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
GlobeNewswire · Oct 26, 2026 8:16 AM ET
Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
GlobeNewswire · Oct 12, 2026 8:07 AM ET
Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud
InvestorsHub · Oct 7, 2026 10:03 AM ET
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
GlobeNewswire · Oct 7, 2026 7:32 AM ET
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
GlobeNewswire · Sep 24, 2026 7:50 AM ET
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
GlobeNewswire · Sep 23, 2026 7:07 AM ET
Financial Overview - Income Statement
Quarterly
Sep 2025
See NXTS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.